EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA

The aim of this study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) combined with complete decongestive therapy (CDT) compared with CDT alone in patients with breast cancer-related lymphedema. Female patients with unilateral Stage II upper-extremity lymphedema related to breast cancer will be included. Participants will receive either complete decongestive therapy alone or complete decongestive therapy combined with extracorporeal shock wave therapy. Clinical outcomes will be evaluated before treatment, immediately after treatment, and at 1 and 3 months after t

Trial Details

NCT ID
NCT07854262
Phase
NA
Sponsor
Ankara City Hospital Bilkent
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Complete Decongestive Therapy
  • Extracorporeal Shock Wave Therapy
Locations (sample)
  • Ankara, Turkey (Türkiye)|39.91987,32.85427

Key Eligibility Criteria

  • At least 2 years have elapsed since the diagnosis of breast cancer, cancer treatment has been completed, and cure has been documented during oncolo…
  • Stage II lymphedema according to the International Society of Lymphology classification.
  • Duration of lymphedema of less than 4 years.
  • Voluntary participation in the study. -

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →